Brainstorm Cell Therapeutics Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Brainstorm Cell Therapeutics Inc (BCLI) Profile and Financials, plus Biotechnology Industry Trends Analysis, Operating Ratios and Financial Averages
Provider: Plunkett Research, Ltd.
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Brainstorm Cell Therapeutics Inc's NurOwn Cell Therapy Receives Orphan Drug Designation In European Union For Als
BrainStorm Cell Therapeutics Inc announced that the European Commission has granted Orphan Drug Designation for NurOwn, the Company's stem cell therapy consisting of autologous bone marrow-derived mesenchymal stromal cells secreting neurotrophic factors, for the treatment of Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's Disease. NurOwn received Orphan Drug Designation from the Food and Drug Administration (FDA) in 2011.
Latest Developments for Brainstorm Cell Therapuetics Inc
Latest Key Developments in Biotechnology
- Avita Medical Ltd announces senior management changes
- PDL BioPharma Inc gives Q4 2013 guidance in line with analysts' estimates
- Lorus Therapeutics Inc completes $7,001,500 prospectus offering of common shares
- KaloBios Pharmaceuticals Inc announces preliminary phase 1 results in advanced hematologic malignancies with kb004, an anti-epha3 monoclonal antibody
- Share this
- Digg this